Clinical Trials Logo

Clinical Trial Summary

This study aims to confirm whether the preventive use of ursodeoxycholic acid on the 5th day after birth in preterm infants who started parenteral nutrition therapy can reduce the occurrence of enteral nutrition-related cholestasis in preterm infants. This study examined the safety and efficacy of ursodeoxycholic acid (UDCA) in preventing Cholestasis Associated with Total Parenteral Nutrition in preterm infants.


Clinical Trial Description

Investigators compared oral administration of UDCA prophylaxis with no prophylaxis in a randomized, open-label, proof-of-concept trial in preterm neonates with PN therapy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05043194
Study type Interventional
Source Tongji Hospital
Contact
Status Recruiting
Phase N/A
Start date January 1, 2021
Completion date July 30, 2022

See also
  Status Clinical Trial Phase
Completed NCT00738101 - Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants N/A
Completed NCT03662282 - Omegaven as Alternative Parenteral Fat Nutrition Phase 3
Completed NCT03387579 - Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates Phase 3
Completed NCT02370251 - Compassionate Use of Omegaven in Children Phase 2/Phase 3
Completed NCT01072721 - Non Invasive Study of the Hepatic Fibrosis in Paediatrics by the Method of Study of Pediatric Hepatic Fibrosis N/A
Approved for marketing NCT01861834 - Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage